In the last trading session, 5.0 million shares of the Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) were traded, and its beta was 2.75. Most recently the company’s share price was $0.29, and it changed around $0.01 or 3.86% from the last close, which brings the market valuation of the company to $74.41M. ADAP currently trades at a discount to its 52-week high of $1.65, offering almost -468.97% off that amount. The share price’s 52-week low was $0.26, which indicates that the current value has risen by an impressive 10.34% since then. We note from Adaptimmune Therapeutics Plc ADR’s average daily trading volume that its 10-day average is 2.87 million shares, with the 3-month average coming to 1.54 million.
Adaptimmune Therapeutics Plc ADR stock received a consensus recommendation rating of Buy, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended ADAP as a Hold, whereas 4 deemed it a Buy, and 1 rated it as Underweight. Adaptimmune Therapeutics Plc ADR is expected to report earnings per share of -0.15 for the current quarter.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Instantly ADAP has showed a green trend with a performance of 3.86% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.4738 on recent trading dayincreased the stock’s daily price by 38.79%. The company’s shares are currently down -46.02% year-to-date, but still down -35.42% over the last five days. On the other hand, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) is -49.82% down in the 30-day period. We can see from the shorts that 6.36 million shares have been sold at a short interest cover period of 7.43 day(s).
The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 90.33% from its current value. Analyst projections state that ADAP is forecast to be at a low of $1 and a high of $4.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
The year-over-year growth rate is expected to be 203.55%, up from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of 8.18M in revenue for the current quarter. 4 analysts expect Adaptimmune Therapeutics Plc ADR to make 5.83M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 231k and 5.68M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 3,441.67%. Forecasts for the next quarter put sales growth at 2.59%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 10.30%.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR’s next quarterly earnings report is expected to be released on 2024-Nov-12.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.31% of Adaptimmune Therapeutics Plc ADR shares, and 49.85% of them are in the hands of institutional investors. The stock currently has a share float of 50.01%. Adaptimmune Therapeutics Plc ADR stock is held by 94.0 institutions, with MATRIX CAPITAL MANAGEMENT COMPANY, LP being the largest institutional investor. By 2024-06-30, it held 2.5415% of the shares, which is about 38.97 million shares worth $38.0 million.
BANK OF AMERICA CORP /DE/, with 1.9239% or 4.65 million shares worth $4.53 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
